Lung cancer remains the leading cause of cancer-related mortality worldwide, with a five-year survival rate of approximately 20–25% despite advances in targeted therapy and immunotherapy. There is a continuous need for novel, low-toxicity compounds capable of modulating key oncogenic pathways in non-small cell lung can...
Z. Mahdi, B. Almjalawi, Mollah Naimuzzaman et al.· PLoS ONE· 0 citations
ABSTRACT Background Exosomes are naturally secreted nanovesicles with high biocompatibility, low immunogenicity, and the ability to traverse biological barriers, making them attractive theragnostic carriers. When engineered to present tumor‐specific antibodies and to deliver antibody‐drug conjugates (ADCs), they may en...
S. Sarkar, Avinaba Bose, Jenifer Rajak et al.· Health Science Reports· 0 citations
The results identify Cardenolide as a computationally prioritized candidate with favorable predicted EGFR-binding characteristics, structural stability, and physicochemical and toxicity profiles and illustrate the potential of Adenium obesum phytochemicals as a source of candidate EGFR-targeting compounds for future NS...
Md. Naziur Rahman, Abu Yousuf Hossin, S. Talukder et al.· PLoS ONE· 0 citations
This review traces the evolution of PROTAC technology, delineates the challenges of conventional delivery, and evaluates the rationale for exosomal encapsulation, including cargo protection, intracellular trafficking, endosomal escape, and release kinetics and outlines future directions for exosome‐mediated targeted pr...
S. Ghosh, R. Banerjee, Hailah M. Almohaimeed et al.· Journal of Cellular and Mole...· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.
